Financial report
|
kEUR |
2021 |
2020 |
2019 |
|
|
|
|
|
|
Income and expenses |
|
|
|
|
Revenue |
282,126 |
223,033 |
202,613 |
|
Custom Projects |
167,006 |
101,872 |
84,288 |
|
Contract Manufacturing |
89,600 |
100,108 |
99,505 |
|
Generics & Cosmetics |
25,520 |
21,053 |
18,820 |
|
Total income |
286,217 |
224,811 |
203,768 |
|
Cost of sales |
-182,426 |
-151,108 |
-144,323 |
|
Total operating expenses |
-39,626 |
-29,325 |
-25,896 |
|
o/w Depreciation and amortization |
-20,683 |
-17,545 |
-15,808 |
|
Financial income |
653 |
106 |
70 |
|
Financial expenses |
-4,970 |
-6,799 |
-3,386 |
|
Income tax charges |
-12,590 |
-6,350 |
-4,496 |
|
Result for the year |
47,258 |
31,335 |
25,737 |
|
|
|
|
|
|
Performance |
|
|
|
|
Gross profit |
103,791 |
73,703 |
59,445 |
|
Gross margin in % of revenue |
36.8% |
33.0% |
29.3% |
|
EBITDA |
84,848 |
61,923 |
49,357 |
|
Adjusted 2 EBITDA |
88,199 |
61,958 |
51,057 |
|
Adjusted 2 EBITDA in % of revenue |
31.3% |
27.8% |
25.2% |
|
Operating result (EBIT) |
64,165 |
44,378 |
33,549 |
|
Operating result (EBIT) in % of revenue |
22.7% |
19.9% |
16.6% |
|
Earnings per share (EUR), basic 3 |
1.47 |
1.04 |
0.86 |
|
Proposed cash distribution per share (CHF) 4 |
0.30 |
0.00 |
0.00 |
|
Return on net operating assets (RONOA) |
21.0% |
18.2% |
15.3% |
|
|
|
|
|
|
Financial position |
|
|
|
|
Total assets |
595,038 |
375,975 |
305,142 |
|
Non-current assets |
263,432 |
196,113 |
162,473 |
|
Current assets |
331,606 |
179,862 |
142,669 |
|
Total equity and liabilities |
595,038 |
375,975 |
305,142 |
|
Equity |
421,173 |
177,660 |
149,416 |
|
Non-current liabilities |
69,904 |
96,467 |
97,789 |
|
Curent liabiliities |
103,961 |
101,848 |
57,937 |
|
|
|
|
|
|
Cash flows 5 |
|
|
|
|
Net cash flows from operating activities |
57,352 |
49,482 |
55,600 |
|
Net cash flows from investing activities |
-80,845 |
-42,560 |
-12,261 |
|
Net cash flows from financing activities |
130,928 |
-6,730 |
-35,937 |
|
Cash and cash equivalents at the end of the year |
136,303 |
17,208 |
17,508 |
|
|
|
|
|
|
Employees |
|
|
|
|
Employees (# of FTEs, average) |
1,041 |
910 |
839 |
1 This table includes references to operational indicators, such as customer projects, and alternative financial performance measures (APM) that are not defined or specified by IFRS. These APM should be regarded as complementary information to and not as substitutes of the Group’s consolidated financial results based on IFRS. For the definitions of the main operational indicators and APM used, including related abbreviations, as well as for selected reconciliations to IFRS, please refer to the section “Definitions and reconciliations” of this report.
2 2021: Adjusted for one-off IPO costs and US government loans waived in the context of the coronavirus pandemic. 2020: Adjusted for equipment damage provision and costs related to the IPO. 2019: Adjusted for equipment damage provision.
3 As described in the first section of the notes to the consolidated financial statements, the parent company of the Group changed during 2021. However, due to the predecessor accounting for this reorganization, basic earnings per share for 2020 and 2019 has been calculated based on the total number of outstanding shares of 30,000,001, corresponding to the share capital of PolyPeptide Group AG prior to the capital increase of 3,125,000 shares, cf. the description in note 7 to the consolidated financial statements.
4 Cash distribution 2021 proposed to the AGM on 26 April, 2022.
5 Changes to the presentation of cash flows were made in the Annual Report 2021 and in the Annual Report 2020. The cash flows for 2021 and 2020 in the table above are based on the consolidated cash flow statement in the Annual Report 2021. The cash flows for 2019 in the table above are based on the consolidated cash flow statement in the Annual Report 2020.